REG - Oxford Biomedica PLC - Result of AGM

Oxford BioMedicaAnnouncement

27/05/2022 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220527:nRSa1528Na&default-theme=true

RNS Number : 1528N  Oxford Biomedica PLC  27 May 2022

 

 

 

Oxford Biomedica

Result of Annual General Meeting

 

Oxford, UK - 27 May 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a leading gene and cell therapy group, announces today that
all resolutions proposed were duly passed at its Annual General Meeting (AGM),
held at 3pm on 27 May 2022 in Oxford. As proposed in the Notice of AGM, all
resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by
visiting the Company's website at www.oxb.com (http://www.oxb.com)

 

Copies of the document setting out the above resolutions passed at the 2022
AGM have been submitted to the National Storage Mechanism and will shortly be
available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

On the Record Date (25 May 2022) there were 96,063,479 ordinary shares of 50
pence each in issue, each carrying one vote per share.

 

                                                                                                                                       Votes at                                           Result

                                                                                      Votes                                            other proxy   Votes       Votes       Total

                                                                                      For (incl. votes at the Chairman's discretion)   Discretion    Against     Withheld*   votes cast

      Resolution

      Ordinary resolutions

 1    To receive the Company's  Accounts, the Reports of the Directors and Auditor    71,533,247                                       0             3,804       907,786     71,537,051   Passed

    and the Strategic Report for the year ended 31 December 2021.

                                                                                      (99.99%)                                                       (0.01%)

 2    To receive the Directors' Remuneration Report and the Report of the Auditor on  57,808,878                                       0             13,801,220  834,739     71,610,098   Passed

    the Remuneration Report for the year ended 31 December 2021.

                                                                                      (80.73%)                                                       (19.27%)

 3    To appoint Dr. Michael Hayden as a Director.                                    62,539,719                                       0             9,295,954   609,164     71,835,673   Passed

                                                                                      (87.06%)                                                       (12.94%)

 4    To appoint Catherine Moukheibir as a Director.                                  71,748,494                                       0             86,921      609,422     71,835,415   Passed

                                                                                      (99.88%)                                                       (0.12%)

 5    To appoint Namrata P. Patel as a Director.                                      71,746,512                                       0             88,903      609,422     71,835,415   Passed

                                                                                      (99.88%)                                                       (0.12%)

 6    To reappoint Dr. Roch Doliveux as a Director.                                   68,788,280                                       0             2,264,491   1,392,066   71,052,771   Passed

                                                                                      (96.81%)                                                       (3.19%)

 7    To reappoint Professor Dame Kay Davies as a Director.                           69,259,453                                       0             2,575,962   609,422     71,835,415   Passed

                                                                                      (96.41%)                                                       (3.59%)

 8    To reappoint Dr. Siyamak Rasty as a Director.                                   71,719,604                                       0             116,069     609,164     71,835,673   Passed

                                                                                      (99.84%)                                                       (0.16%)

 9    To reappoint Stuart Paynter as a Director.                                      71,206,012                                       0             629,661     609,164     71,835,673   Passed

                                                                                      (99.12%)                                                       (0.88%)

 10   To reappoint Stuart Henderson as a Director.                                    67,003,486                                       0             4,832,187   609,164     71,835,673   Passed

                                                                                      (93.27%)                                                       (6.73%)

 11   To reappoint Dr. Heather Preston as a Director                                  64,708,975                                       0             7,126,698   609,164     71,835,673   Passed

                                                                                      (90.08%)                                                       (9.92%)

 12   To reappoint Robert Ghenchev as a Director.                                     71,526,110                                       0             309,305     609,422     71,835,415   Passed

                                                                                      (99.57%)                                                       (0.43%)

 13   To reappoint KMPG LLP as auditor.                                               71,831,890                                       0             7,494       605,453     71,839,384   Passed

                                                                                      (99.99%)                                                       (0.01%)

 14   To authorise the Directors to agree the remuneration of the auditor.            71,832,849                                       0             6,921       605,067     71,839,770   Passed

                                                                                      (99.99%)                                                       (0.01%)

 15   To authorise the Directors to allot shares.                                     67,355,882                                       0             4,471,767   617,188     71,827,649   Passed

                                                                                      (93.77%)                                                       (6.23%)

      Special resolutions

 16   To authorise the Directors to disapply pre-emption rights.                      70,888,310                                       0             937,061     619,466     71,825,371   Passed

                                                                                      (98.70%)                                                       (1.30%)

 17   To authorise the Directors to further disapply pre-emption rights for           70,922,796                                       0             903,407     618,634     71,826,203   Passed

    acquisitions and specified capital investments.

                                                                                      (98.74%)                                                       (1.26%)

 18   To permit the Directors to convene general meetings (other than annual general  69,350,429                                       0             2,489,321   605,087     71,839,750   Passed

    meetings) on not less than 14 days' notice.

                                                                                      (96.53%)                                                       (3.47%)

 

* A vote withheld is not a vote in law and is not counted towards votes cast
in respect of a resolution.

 

In addition, further to the announcements by the Company in January and April,
John Dawson has stepped down from the Company's Board of Directors after more
than thirteen years of service with effect from the conclusion of today's AGM.

 

 

-Ends-

 

 

 Enquiries:

 Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
 Stuart Paynter, Chief Financial Officer

 Sophia Bolhassan, Head of Investor Relations
 Consilium Strategic Communications:

 T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 Mary-Jane Elliott / Matthew Neal / Matthew Cole

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (http://www.oxb.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEUFMWEESEII